After Hours 11 Mar 2026: KALA BIO (KALA NASDAQ) up 24.16% to $0.36, model sees upside

KALA stock jumped in after-hours trade on 11 Mar 2026 after Kala Bio, Inc. (KALA) said it will ship its first commercial AI agent. The Nasdaq-listed biotechnology name moved from the regular session close of $0.29 to $0.36 after hours, a 24.16% move on 286,456,832 shares. This surge made KALA one of the most active U.S. stocks in after-hours trading and ties the company’s clinical-stage biotech profile to a new AI-driven growth narrative.

KALA stock: after-hours move and volume

KALA stock posted a strong after-hours uptick on 11 Mar 2026, rising 24.16% to $0.36 from a prior close of $0.29. The trade was heavy, with reported volume at 286,456,832 versus an average daily volume of 1,481,666, marking a relative volume surge and making KALA one of the day’s most active names.

KALA stock news: AI agent launch drove the rally

Kala Bio announced plans to ship its first commercial AI agent, Researgency.ai, a move the market tied to the after-hours rally. Coverage from business outlets highlighted the launch timeline and strategy shift toward agentic AI for biotech clients. See the company release and coverage for detail on product timing and scope at Business Insider Markets and Investing.com.

KALA stock: fundamentals and valuation snapshot

Kala Bio is a U.S. Nasdaq-listed biotechnology firm focused on nanoparticle delivery for eye disease; its market cap stands near $8,002,257.00 with 21,930,000 shares outstanding. Recent key metrics show EPS -5.64, P/E -0.06, and cash per share roughly 2.99. The 50-day average price is $0.49 and the 200-day average is $4.12, underscoring long-term weakness versus the recent short-term bounce.

KALA stock technicals and most-active trading signals

Technically, KALA stock has an RSI of 37.75 and an ADX of 40.76, indicating a strong trend environment but room before oversold/overbought extremes. Bollinger bands show a middle band at $0.37 and an upper band at $0.46, which frames the after-hours price action. The intraday high reached $0.51, suggesting short-term momentum following the news.

Meyka AI rates KALA with a score out of 100 and forecast

Meyka AI rates KALA with a score out of 100: 71.81 (B+) — BUY. This grade factors in S&P 500 benchmark comparison, sector performance, financial growth, key metrics, and analyst consensus. Meyka AI’s forecast model projects a yearly price of $2.97 compared with the current price USD 0.3649, implying a theoretical upside of 714.44%. Forecasts are model-based projections and not guarantees. For more on the stock page see the Meyka analysis hub: KALA at Meyka.

KALA stock risks and near-term outlook

KALA stock carries biotech and execution risk: negative operating margins, a current ratio of 0.75, and high research spend (R&D about 92.93% of revenue). The enterprise value to sales and cash runway metrics point to capital sensitivity. Investors should weigh the AI pivot against clinical milestones and cash flow before treating this as a trade rather than a long-term position.

Final Thoughts

KALA stock’s after-hours surge on 11 Mar 2026 reflects market enthusiasm for Kala Bio’s entry into commercial AI agents and heavy trading interest. The price moved to $0.36 on 286,456,832 shares, making it one of the most active Nasdaq stocks in after-hours trade. Fundamentals remain challenged: EPS -5.64, P/E -0.06, and a 200-day average of $4.12 show long-term pressure. Meyka AI’s forecast model projects a yearly price of $2.97, implying a model-based upside of 714.44% versus the current price USD 0.3649; these projections are not guarantees. Our view: the AI product news is a valid catalyst for short-term momentum, but investors should balance speculative upside against weak cash flow metrics and sector volatility. Use volume and catalyst-based exits, and monitor the company’s upcoming earnings announcement on 2026-03-26 for clearer signs of execution and revenue progress. Meyka AI-powered market analysis flagged KALA as a high-risk, high-reward name for active traders rather than passive portfolios.

FAQs

Disclaimer:

Stock markets involve risks. This content is for informational purposes only. Past performance does not guarantee future results. Meyka AI PTY LTD provides market analysis and data insights, not financial advice. Always conduct your own research and consider consulting a licensed financial advisor.